Answers are grounded in this paper and cite their sources.
Kidney damage due to ischemia-reperfusion injury (IRI) is a serious cause of morbidity and mortality. We induced an experimental kidney ischemia-reperfusion model in rats where intraperitoneal dexpanthenol were given and compared to controls in terms of oxidative stress, tubular damage, apoptosis, and its effect on renal inflammation. Twelve-week-old male albino Wistar rats were used for creating the experimental model and the study sample were divided into three groups (n=16); control group (intraperitoneal 2cc/kg saline was injected), IRI group and IRI+dexpanthenol group via intraperitoneal injection. Blood samples were obtained from rats 24 hours after perfusion and their left kidneys were removed. In order to determine the percentage of apoptotic cells, a total of 100 cells were counted in each region and the number of cells with caspase-3 positivity was recorded for each region. Mortality was lower, although not statistically significant in the IRI+dexpanthenol group (n=3; 18.8%) compared to the IRI group (n=6; 37.5%) (p=0.216). In addition, kidney parenchyma and tubular damages were significantly lower in the dexpanthenol group compared to the IRI group (p<0.05). Dexpanthenol significantly decreased oxidative stress and inflammation. Caspase-3 positive stained cell numbers were lower in the dexpanthenol group and also apoptosis rates were significantly lower (p<0.05). Dexpanthenol treatment in kidney ischemia-reperfusion models showed significant recovery in kidney tubular cell and parenchyma damages, apoptosis, oxidative stress, and inflammation. These results show us that dexpanthenol treatment can be a promising alternative in improving the prognosis of adults with kidney IRI.
No takes yet. Share an insight, caveat, or question.
Arslan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: